BIOTOSCANA INVESTMENTS S.A.
Corporate Taxpayer’s ID (CNPJ / MF): 19.688.956./0001-56
24, Rue Beck, L 1222, Luxembourg
Legal representative in Brazil: Av. Dos Imarês, 401, São Paulo, SP

NOTICE TO THE MARKET

BIOTOSCANA INVESTMENTS SA ("Company" or "GBT") (B3: GBIO33), one of the largest biopharmaceutical groups in Latin America, hereby presents, within the scope of the Official Letter no. 792/2018-SAE /GAE-1 issued by the B3 Company Relations Superintendence on April 27, 2018 (" Official Letter "), copy transcribed at the end, the following clarifications:

The Official Letter concerned the deliberations of the Company’s General Meeting requesting:

"Considering the resolutions of the meeting held on April 25, 2018, we request that the end date of the Share Buyback Program be informed by May 30, 2018. "

The Company informs that it spoke by telephone with B3 on April 27, 2018 and reported that it was in the process of opening a custody account to enable the repurchase of the BDRs. Thus, in the Material Fact published on April 25 (date when the Company’s General Meeting was held), we informed that the Buyback Program will start in May, 2018. However, it was not possible to ascertain exactly what date the repurchase would begin, since it depended on the opening of said account.
The Company undertook to promptly inform the B3 and the CVM, through email, and also to issue the Notice to the Market - Clarifications on CVM/B3’s inquiries, via IPE system, once the start and end dates of the program are defined.
Through this announcement, the Company informs that the repurchase program will start on May 11, 2018, for a term of up to 18 months, ending on October 11, 2018.

The Official Letter is transcribed below:
Ref.: Share Buyback

Dear Sir,

Considering the resolutions of the meeting held on April 25, 2018, we request that the end date of the Share Buyback Program be informed by May 30, 2018.

The response to be sent must state the subject matter of the inquiry above, before the statement of this company. This paragraph, as well as the paragraphs below must be omitted in your answer.

This request relates to the Cooperation Agreement entered into by and between CVM and B3 on December 13, 2011, and failure to comply with it may make the company subject to penalties by the Company Relations Superintendence – SEP of the CVM, as set forth in CVM Instruction No. 452/07.

The response of this company must be sent using the IPE module, selecting Category: Notice to the Market, Type: Clarifications on inquiries from CVM/B3, which shall result in simultaneous transmission of the file to B3 and CVM.

To learn more about the activities carried out by the Issuers Management Office, please log on to B3 new website: http://www.bmfbovespa.com.br/pt_br/regulacao/regulacao-de-emissores (Home/ Regulação/ Regulação de emissores).

If you have any questions, please contact the Company Relations Office at (11) 2565-7143.

Sincerely,

Marcelo Santos Heliodorio
Bureau of Company Relations and Variable Income Securities Offering 1
B3 – Brasil, Bolsa, Balcão
About GBT-Biotoscana Group
GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical, LKM and DOSA. GBT’s strong portfolio combines world-class licenses and proprietary products. To find out more about Grupo Biotoscana, please go to www.grupobiotoscana.com.